Introduction
Cartilage helps joints move smoothly, cushioning the bones and absorbing load. When it wears, joints can become painful and stiff. This article explains what ChondroFiller is, how the injection works, where it may be considered, and what realistic expectations look like for patients exploring non-surgical joint-preservation options.
Understanding Joint Wear
Joint wear can arise from ageing, repetitive use, sports injury, or trauma. Common signs include pain, stiffness, swelling, and limited movement. Because articular cartilage has a limited capacity for self-repair, options that support the joint environment rather than simply masking symptoms are of growing clinical interest.
What Is ChondroFiller?
ChondroFiller is a Class III CE-marked medical device manufactured by Meidrix Biomedicals in Germany. It is an acellular (cell-free) type I collagen hydrogel: a liquid that, once placed inside the joint, self-gels within approximately three to five minutes, forming a porous scaffold. The device is imported into the UK under prescription and its CE marking and published clinical evidence belong to the device itself.
The scaffold is designed to act as a chemotactic matrix, attracting the patient's own progenitor cells from the surrounding tissue and subchondral bone. Over time — typically one to two years — the implanted collagen is gradually resorbed and replaced by patient-derived hyaline-like cartilage tissue. The biological process is supportive and regenerative in intent, but outcomes vary and cartilage regrowth cannot be guaranteed.
The ChondroFiller Injection: A Non-Surgical Delivery Pathway
When delivered as an outpatient procedure, ChondroFiller is given as an ultrasound-guided injection into the joint. No theatre, no incision, and no general anaesthetic are required. This non-surgical route is suited to accessible lesions and smaller joints where the scaffold can be placed precisely under imaging guidance. Recovery is typically quicker and less disruptive than surgery, though activity guidance following the injection is important to allow the gel to stabilise.
For larger or load-bearing defects — in joints such as the knee, hip, or shoulder — the ChondroFiller scaffold may instead be delivered arthroscopically as part of the Liquid Cartilage surgical protocol, which is a distinct keyhole procedure and a separate clinical pathway. Patients whose assessment points towards surgery will be advised accordingly.
Benefits and Where It May Be Considered
A principal benefit of the injection route is its non-surgical nature, which generally means a shorter recovery and less procedural risk than keyhole or open surgery. It may be considered for various joints, including the knee, ankle, hip, and small joints of the hand and thumb, in appropriately selected patients.
A 2023 study of thumb-base (trapeziometacarpal) osteoarthritis reported improvements in pain and grip strength following ChondroFiller use (Corain, Zanotti, Giardini, Gasperotti, Invernizzi, Biasi and Lavagnolo, 2023, Cartilage). Published clinical data across knee and hip applications indicate that International Knee Documentation Committee (IKDC) scores improve by approximately 30 points over 12 to 36 months, and modified Harris Hip Score (mHHS) improves by more than 30 points in hip cases. Imaging with MOCART scoring at follow-up in published series has shown values around 80 and above, consistent with good-quality defect fill. These figures reflect the device's evidence base and should not be read as guaranteed outcomes for any individual.
Risks and Guidance
As with any joint injection, there are minor procedural risks, including local irritation, temporary discomfort, or, rarely, infection. The gel can occasionally fail to set correctly if handling conditions are not optimal, though this is rare in experienced hands. Responses to treatment vary and benefits cannot be guaranteed. A thorough specialist assessment is needed to determine whether the injection is appropriate, taking into account the joint involved, defect size, degree of arthritis, and individual health factors.
Conclusion
ChondroFiller is a non-surgical, ultrasound-guided collagen hydrogel injection that may help support a worn joint and ease symptoms for some patients. Its CE-marked scaffold works by providing a regenerative matrix for the body's own cells, rather than simply cushioning the joint. For patients with more significant defects or larger joints, a surgical assessment — such as that offered through the Liquid Cartilage protocol — may also be appropriate. For tailored advice and an honest appraisal of suitability, a consultation with a specialist in cartilage and joint preservation at the London Cartilage Clinic can help clarify which pathway, if any, is right for you.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., and Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- ChondroFiller is a CE-marked, cell-free type I collagen hydrogel that is injected into the joint under ultrasound guidance as an outpatient procedure. Once inside the joint it self-gels within three to five minutes, forming a porous scaffold. The patient's own progenitor cells migrate into this scaffold and, over one to two years, the collagen is gradually replaced by hyaline-like cartilage tissue. It is not surgery and does not cure arthritis; it supports the joint's natural repair environment.
- Yes. The ChondroFiller injection is a non-surgical, outpatient procedure delivered under ultrasound guidance — no theatre, incision, or general anaesthetic is needed. Separately, the same ChondroFiller scaffold can be placed arthroscopically (via keyhole surgery) as part of the Liquid Cartilage surgical protocol, which combines the scaffold with biological adjuncts and is used for larger or load-bearing defects. The two pathways are distinct and the right one depends on individual assessment.
- The ChondroFiller injection has been used in the knee, hip, ankle, shoulder, and small joints including the thumb base. Suitability depends on the joint location, defect size, degree of wear, and overall joint health. Not all joints or defect sizes are suited to the injection route; some cases are better managed surgically. A specialist assessment is the starting point.
- Because it avoids surgery, the injection route generally allows a quicker return to normal daily activities compared with keyhole procedures. Recovery guidance still applies to allow the scaffold to stabilise, and benefits vary between individuals. It is not a cure and does not stop underlying wear; it is a joint-preservation measure that may reduce symptoms and support the biological environment of the joint.
- Key discussion points include: whether the ChondroFiller injection or a surgical pathway is more appropriate for your defect and joint, realistic expectations for symptom improvement, the minor procedural risks involved, and what activity restrictions apply afterwards. A full assessment of joint health, imaging, and general fitness is needed before any decision is made.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
